Diffusion-Weighted Imaging Prior to Percutaneous Sclerotherapy of Venous Malformations—Proof of Concept Study for Prediction of Clinical Outcome

Autor: Mirjam Gerwing, Philipp Schindler, Kristian Nikolaus Schneider, Benedikt Sundermann, Michael Köhler, Anna-Christina Stamm, Vanessa Franziska Schmidt, Sybille Perkowski, Niklas Deventer, Walter L. Heindel, Moritz Wildgruber, Max Masthoff

Publikováno v: Diagnostics, Vol 12, Iss 6, p 1430 (2022)

Prediction of response to percutaneous sclerotherapy in patients with venous malformations (VM) is currently not possible with baseline clinical or imaging characteristics. This prospective single-center study aimed to predict treatment outcome of pe

Externí odkaz: https://doaj.org/article/6f0f30db577749d0b2bf26205a5925ab

Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma

Autor: Lutz Meyer, Richard Brill, Wibke Uller, Regina Schinner, Franziska Ziermann, Vanessa Franziska Schmidt, Jochen Rössler, Peter B. Sporns, Katrin Funke, Irene Schmid, Christian Güttel, Melchior Lauten, Beate Häberle, Esther Heid, Moritz Wildgruber, Axel Schmid, Dieter Hüsemann, Anne-Marie Till, Sybille Perkowski, Alexandra Pohl, Veronika Huf, Jens Ricke, René Müller-Wille, Walter A. Wohlgemuth, Jacob Neumann, Friedrich G. Kapp

Publikováno v: Brill, Richard; Uller, Wibke; Huf, Veronika; Müller-Wille, René; Schmid, Irene; Pohl, Alexandra; Häberle, Beate; Perkowski, Sybille; Funke, Katrin; Till, Anne-Marie; Lauten, Melchior; Neumann, Jacob; Güttel, Christian; Heid, Esther; Ziermann, Franziska; Schmid, Axel; Hüsemann, Dieter; Meyer, Lutz; Sporns, Peter B; Schinner, Regina; ... (2021). Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma. International journal of cancer, 148(9), pp. 2345-2351. Wiley-Blackwell 10.1002/ijc.33406

Purpose: Kaposiform Hemangioendothelioma (KHE) is a rare vascular tumor in children, which can be accompanied by life-threatening thrombocytopenia, referred to as Kasabach-Merritt Phenomenon (KMP). The mTOR inhibitor sirolimus is emerging as targeted

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c699643bd3f979cfe1a3514223f32e8
https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/15926